A mitochondrial-derived peptide studied for metabolic flexibility and exercise-like signaling.
MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA rather than the nuclear genome — one of a small class of 'mitochondrial-derived peptides' discovered in the last decade. Preclinical research describes AMPK activation, improved insulin sensitivity, and mitochondrial-to-nuclear signaling that mimics some effects of exercise. Human trial data is still sparse, and we prescribe it off-label with that stated plainly.
Preclinical models show MOTS-c activates AMPK, the same cellular energy-sensing pathway engaged by exercise and caloric restriction.
Animal studies describe improved glucose uptake in skeletal muscle and resistance to diet- and age-induced insulin resistance.
MOTS-c is one of the few known signals that travels from mitochondria to the cell nucleus under metabolic stress, adjusting gene expression to support energy adaptation.
Circulating MOTS-c rises with exercise in human studies, which is part of why it is described as 'exercise mimetic' — but it is a complement to training, not a substitute for it.
Commonly stacked with NAD+ for patients already focused on cellular energy and metabolic healthspan.
Works through cellular energy sensing rather than growth hormone or incretin pathways, giving it a distinct mechanism from other peptides on this site.
Most peptides act like a hormone or growth factor. MOTS-c is different — it is produced from a short open reading frame inside the mitochondrial genome and appears to function as a stress signal that reports the cell's energy status to the nucleus.
Under energetic stress, MOTS-c is produced and can translocate toward the nucleus, acting as a retrograde signal from mitochondria to the cell's genetic machinery.
MOTS-c activates AMPK, the enzyme that shifts cells toward fat oxidation and away from storage when energy is scarce.
In animal models, this translates to improved insulin-independent glucose uptake in muscle tissue.
Circulating MOTS-c levels appear to decline with age in preclinical models, part of the rationale for exploring it as a metabolic-support peptide in adults.
MOTS-c research is young. The foundational work is in mice and cell culture; human data is limited to observational studies of circulating MOTS-c around exercise, not controlled trials of therapeutic injection. We prescribe it off-label as an emerging peptide, not a proven metabolic therapy, and your physician will be direct with you about that distinction.
MOTS-c is widely sold online as an unregulated research chemical of inconsistent purity. Ours is compounded by a licensed U.S. pharmacy under physician prescription with certificates of analysis for identity and potency.
The 'exercise mimetic' framing describes a shared pathway, not an equivalent outcome. We do not position MOTS-c as a replacement for resistance training or cardiovascular exercise — it is discussed as a possible complement for patients already training consistently.
MOTS-c has not been individually named on the WADA Prohibited List, but peptide and metabolic-modulator enforcement is an active area. Competitive athletes subject to testing should get sport-specific guidance before using any investigational peptide.
First characterization of MOTS-c as a mitochondrial-derived peptide that regulates insulin sensitivity and prevents diet-induced obesity in mouse models.
Cell Metabolism
Circulating MOTS-c rises with exercise and declines with age; MOTS-c administration improved age-related physical decline and muscle function in mouse models.
Nature Communications
Illustrative only. Your physician sets and adjusts your schedule based on tolerance, labs and rate of progress — escalation is never automatic.
| Phase | Dose | Clinical note |
|---|---|---|
| Weeks 1–2 | 5 mg twice weekly | Assess tolerance. |
| Weeks 3–8 | 5–10 mg 2–3x weekly | Titrated against response and injection tolerance. |
| Weeks 9–10 | Taper toward washout | Reassess before a subsequent cycle. |
| Washout | — | 2–4 weeks off before repeating a cycle. |
Most side effects are dose-dependent and resolve with slower titration. Your care team is reachable by message, and holding a dose is always an option.
| Therapy | Mechanism | Avg. weight change | Frequency |
|---|---|---|---|
| MOTS-c | Mitochondrial-derived peptide, AMPK activation | — | 2–3x weekly |
| NAD+ Injectable | Direct coenzyme repletion | — | 2–3x weekly |
| CJC-1295 / Ipamorelin | GH secretagogue | — | Nightly |
No. It is an emerging peptide prescribed off-label and compounded by a licensed U.S. pharmacy. Human trial data is limited to observational exercise studies, not controlled therapeutic trials, and your physician will review that with you.
No. MOTS-c shares a signaling pathway with exercise, but it is discussed as a complement to a training program, not a substitute for one.
NAD+ replenishes a coenzyme every cell needs for energy production. MOTS-c is a signaling peptide that activates AMPK and communicates cellular energy status to the nucleus. They work through different mechanisms and are sometimes stacked together.
MOTS-c is not individually named on the WADA Prohibited List, but peptide enforcement is active and evolving. If you are drug-tested, get sport-specific guidance before starting.
The clinical gold standard for appetite regulation.
View protocolDual incretin action for the deepest documented weight reduction.
View protocolA gastric peptide studied for systemic tissue repair.
View protocolA synthetic fragment of Thymosin Beta-4 studied for soft-tissue recovery.
View protocolA paired secretagogue protocol that supports your own growth hormone rhythm.
View protocolA mitochondrial cofactor protocol for energy, focus and cellular repair.
View protocolThe same GLP-1 signal, taken as a daily oral dose instead of a weekly injection.
View protocolAn on-demand therapy that works on desire in the brain, not blood flow in the body.
View protocolIntranasal peptides studied for focus, stress resilience and neurotrophic support.
View protocolThe original growth hormone-releasing peptide — simpler and gentler than newer secretagogue combinations.
View protocolA two-minute intake, reviewed by a licensed physician. No obligation, no membership fee.